ABVX:EPA
Abivax SA
79,55 €
arrow_upward
+0,38%(+0,30) 1D
4 nën, 5:38:16 m.d., GMT+1 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për ABVX...
Hap
79,60 €
I lartë
80,85 €
I ulët
78,15 €
Kapitalizimi i tregut
7,31 mld
Vëllimi mesatar
112,48 mijë
Vëllimi
87,75 mijë
Maksimumi 52-javor
139,00 €
Minimumi 52-javor
60,45 €
Fitimet për aksion
-5,20 €
Aksionet në qarkullim
87,55 mln
Numri i punonjësve
98
Hap
79,60 €
I lartë
80,85 €
I ulët
78,15 €
Kapitalizimi i tregut
7,31 mld
Vëllimi mesatar
112,48 mijë
Vëllimi
87,75 mijë
Maksimumi 52-javor
139,00 €
Minimumi 52-javor
60,45 €
Fitimet për aksion
-5,20 €
Aksionet në qarkullim
87,55 mln
Numri i punonjësve
98
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
MarketWatch
·
5 orë më parë
Dow scores its best day in 18 months in a broad relief rally after Democrats sweep to power in Congress
PBS
·
6 orë më parë
U.S. stocks surge, and the Dow soars 1,500 points as Brent oil's price drops below $95 per barrel
Investor's Business Daily
·
1 orë më parë
Futures Mixed After Postelection Rally; Three Giants Are Buys
Profili
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Rreth Abivax SA
Drejtori ekzekutivMarc de Garidel | Hartmut J. Ehrlich
Punonjësit98
Themeluar më4 dhj 2013
Selia-
Sektori-
Industry-
Uebsajtiabivax.com